SCHEMBL24501049

SCHEMBL24501049

Nc1nnc(OCC2CCOCC2)s1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ DHFR P00374 1/20 0.39
▸ DCPS Q96C86 1/20 0.39
▸ POLB P06746 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MCHR1 Q99705 1/20 0.34
▸ FEN1 P39748 1/20 0.34
▸ FFAR2 O15552 1/20 0.32
▸ CCNK O75909 1/20 0.31
▸ CDK9 P50750 1/20 0.31
▸ XDH P47989 2/20 0.30
▸ GRM4 Q14833 2/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ GLS O94925 1/20 0.30
▸ IRAK4 Q9NWZ3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27294311 0.91 MCHR1 (0.43) DHFRDCPSPOLBGAAMCHR1
SCHEMBL22717781 0.90 POLB (0.40) POLBGAASMN1; SMN2GLS
SCHEMBL24501285 0.85 POLB (0.35) POLBGAASMN1; SMN2GLS
SCHEMBL24501494 0.85 POLB (0.47) POLBGAAMCHR1SMN1; SMN2GLS
SCHEMBL19449335 0.85 POLB (0.44) POLBGAAMCHR1SMN1; SMN2GLS
SCHEMBL24501428 0.83 POLB (0.33) POLBGAAMCHR1IRAK4
SCHEMBL24501442 0.82 POLB (0.37) DHFRDCPSPOLBGAA
SCHEMBL31083249 0.80 GLS (0.33) DHFRDCPSPOLBGAASMN1; SMN2
SCHEMBL24500857 0.79 POLB (0.35) POLBGAASMN1; SMN2
SCHEMBL29108213 0.79 POLB (0.32) POLBGAASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325552-A1 SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES INC (US) 2025-10-23 — — US disclosed
CN-117083271-A Substituted thiadiazolyl derivatives as DNA polymerase theta inhibitors 伊迪亚生物科学有限公司 2023-11-17 — — CN disclosed
EP-4255573-A1 SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS Ideaya Biosciences, Inc. (US) 2023-10-11 — — EP disclosed
WO-2022118210-A1 SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2022-06-09 — — WO disclosed
WO-2022118210-A1 SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2022-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250325552-A1 SUBSTITUTED THIADIAZOLYL DERIVATIVES AS DNA POLYMERASE THETA INHIBITORS POLQ, POLK, POLH DHFR 334/4885DCPS 1062/4885POLB 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback